The share price of Cara Therapeutics, Inc. [NASDAQ: CARA] inclined by $16.13, presently trading at $16.75. The company’s shares saw 37.45% gains compared to the lowest price in the period of the last 52 weeks, set at $12.19 recorded on Dec 6, 2019. The last few days have been benevolent to the share price as CARA fall by -35.51% during the last week, even though the stock is still down by -35.48% compared to -9.23 of all time high it touched on 12/02/19. However, the stock had a poor performance during the past 3 months, roughly losing -13.68%, while additionally dropping -2.02% during the last 12 months. Cara Therapeutics, Inc. is said to have a 12-month price target set at $32.11. That means that the stock has a strong potential to acquire 15.36% increase from the current trading price.
Cara Therapeutics, Inc. [NASDAQ:CARA]: Analyst Rating and Earnings
Its stock price has been found in the range of 12.19 to 27.55. This is compared to its latest closing price of $16.13.
Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for Tue 10 Mar (In 93 Days).
Fundamental Analysis of Cara Therapeutics, Inc. [CARA]
Now let’s turn to look at profitability: with a current Operating Margin for Cara Therapeutics, Inc. [CARA] sitting at -574.52.
This company’s Return on Total Capital is -70.22, and its Return on Invested Capital has reached -57.60%. Its Return on Equity is -67.16, and its Return on Assets is -51.43. These metrics suggest that this Cara Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to
What about valuation? This company’s Enterprise Value to EBITDA is -8.06. The Enterprise Value to Sales for this firm is now 29.67. Cara Therapeutics, Inc. [CARA] has a Price to Book Ratio of 3.85.
Shifting the focus to workforce efficiency, Cara Therapeutics, Inc. [CARA] earns $244,891 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 11.02 and its Total Asset Turnover is 0.09. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 4.16 and its Current Ratio is 4.16. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Cara Therapeutics, Inc. [CARA] has 44.94M shares outstanding, amounting to a total market cap of $752.97M. Its stock price has been found in the range of 12.19 to 27.55. At its current price, it has moved down by -39.18% from its 52-week high, and it has moved up 37.45% from its 52-week low.
This stock’s Beta value is currently 2.40, which indicates that it is 9.16% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 33.37. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Cara Therapeutics, Inc. [CARA] a Reliable Buy?
Shares of Cara Therapeutics, Inc. [CARA], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.